FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms

Kotze, Lorete Maria da Silva; Nisihara, Renato; Marion, Sandra Beatriz; Cavassani, Murilo Franco; Kotze, Paulo Gustavo

doi:10.1590/s0004-28032015000100011

Cited by 22 publications

(19 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other causes of loss of response are late complications such as stenosis, fistulas, neoplasia or infections (Clostridium difficile and cytomegalovirus), that produce symptoms and do not respond to biological therapy. There are strategies for monitoring activity of patients with IBD, such as dosage of fecal calprotectin (13) and the evaluation scores of diseases: Crohn's Disease Activity Index (CDAI) for CD (2) ; and the Mayo, Truelove and Witt scores for UC (7) . There are two strategies for optimazing biological therapy: the proactive and the empirical strategies.…”

Section: (9090) Suspendedmentioning

confidence: 99%

Importance of Measuring Levels of Infliximab in Patients Treating Inflammatory Bowel Disease in a Brazilian Cohort

Dbg

et al. 2017

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Background -Crohn's disease and ulcerative colitis are chronic inflammatory bowel diseases. In such pathologies, there is an increased production of alpha tumor necrosis factor (TNF-α). Patients, in whom the conventional immunosuppressant treatment fails, require the use of immunobiological therapy, such as anti-TNF-α, a monoclonal antibody. infliximab is an anti-TNF-α drug, a chimerical immunoglobulin, with a murine component, which is responsible for the generation of immunogenicity against the drug and formation of anti-TNF-α antibodies. The presence of anti-drug antibodies may be responsible for adverse events and reduction of the drug's effectiveness. Patients with inflammatory bowel diseases undergoing therapy with biological medication, such as infliximab, can relapse overtime and this may not be translated into clinical symptoms. Thus, there is a need for a method to evaluate the efficacy of the drug, through the measurement of serum infliximab levels, as well as antibodies research. Objective -This study aimed to measure serum infliximab levels and anti-infliximab antibodies in patients with inflammatory bowel diseases post-induction phase and during maintenance therapy, and describe the therapeutic modifications that took place based on the serum levels results. Methods -It was a retrospective study, that included forty-five patients, with a total of 63 samples of infliximab measurement. Results -Twenty-one patients had an adequate infliximab serum level, 31 had subtherapeutic levels and 11 had supratherapeutic levels. Seven patients had their medication suspended due to therapeutic failure or high levels of antibodies to infliximab. Conclusion -In conclusion, only a third of the patients had adequate infliximab levels and 36% presented with subtherapeutic levels at the end of the induction phase. Therapy optimization occurred based in about 46% of the samples results, demonstrating the importance of having this tool to help the clinical handling of patients with inflammatory bowel diseases ongoing biologic therapy.

show abstract

Section: (9090) Suspendedmentioning

confidence: 99%

Importance of Measuring Levels of Infliximab in Patients Treating Inflammatory Bowel Disease in a Brazilian Cohort

Dbg

et al. 2017

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…Studies investigating whether fecal lactoferrin can be used as a noninvasive marker to distinguish IBD from non inflammatory conditions, especially irritable bowel syndrome (IBS), have yielded variable results (9,10,37) Out of numerous neutrophil derived proteins present in stools, calprotectin a calcium-and zincbinding protein that inhibits metalloproteinase is probably the most promising. It is the major protein found in monocytes, macrophages and constitutes 50-60% of neutrophil cytosolic proteins (38,39). several studies have showed high fecal calprotectin levels are directly correlated with the quantification of the neutrophilic infiltrate in the gut mucosa as an indicator of infectious and inflammatory conditions (14,40).…”

Section: Resultsmentioning

confidence: 99%

Fecal Lactoferrin, Fecal Calprotectin, Transforming growth factor-b1, and CRP in Evaluation of Disease Activity in Egyptian patients With Ulcerative colitis

2017

Int. J. Curr. Res. Med. Sci.

View full text Add to dashboard Cite

Aims: to analyze the usefulness of fecal lactoferrin, fecal calprotectin, transforming growth factor-B1,Endoscopic Activity Index, Clinical Activity Index, C-reactive protein, and blood leucocytes in monitoring disease activity in Egyptian patients with ulcerative colitis. Methods: One hundred and twenty patients with ulcerative colitis were enrolled and scored according to the endoscopic part of the Rachmilewitz Index. Patients and controls: Patients and controls provided fecal and blood samples for measuring Lactoferrin, calprotectin, TGF-B1, CRP, and leucocytes. Results: The values in ulcerative colitis patients (n = 120) compared to controls (n = 30): Fecal lactoferrin: 703.6±657.6 versus7.01±3.9 µg/g, calprotectin: 867.4±561.2 versus 36.3±15.3 μg /g, TGF-B1: 386.9±246.7 versus 5.9±1.8 pg /ml, CRP:19.4±14.7 versus 3.2±0.9 mg/L, blood leucocytes: 11.6±3.8 versus 6.8±1.9 g/L ( for all P< 0.001). Endoscopic disease activity correlated significantly with lactoferrin (Spearman's rank correlation coefficient r =0.949), calprotectin (r = 0.923), TGF-B1 (r = 0.918), Clinical Activity Index (r = 0. 761), CRP (r = 0.851), and blood leucocytes (r = 0.681). Fecal lactoferrin, calprotectin and TGF-B1 levels were significantly lower in ulcerative colitis patients with inactive disease ( endoscopic score 0 -3, Lactoferrin 48.7±24.9 µg/g, calprotectin 81.5 ± 48.8 μg / g, TGF-B1 42.5 ± 36.5 pg/mL , P < 0.001 for both lactoferrin and calprotectin, but P <0.059 for TGF-B1), compared to patients with mild ( score 4 -6, lactoferrin 465.7 ± 217.4 µg/g, calprotectin 420.4 ±244.8 μg/g, TGF-B1 269.6 ± 80.3 pg/mL, P < 0.001 ), moderate ( score 7 -9, lactoferrin 678.7 ± 258.6 µg/g, calprotectin 1074.9 ± 303.5 μg/g, TGF-B1 391.5 ± 56.8 pg/mL, P < 0.001 ), and high disease ( score 10 -12 , lactoferrin 1624.5 ± 327.2 µg/g, calprotectin 1466.5.2 ± 31.5 μg/g, TGF-B1 690.9 ± 160.1 Pg/ mL, P < 0.001). The overall accuracy for detection of histopathological active disease was 96.9 % for fecal lactoferrin, 96.6 for fecal calprotectin, 94.5 % for TGF-B1, 90 % for Endoscopic Activity Index, 87 % for Clinical Activity Index, and 65 % for both blood leucocytes and CRP. Conclusion: Fecal lactoferrin, fecal calprotectin and TGF-B1 correlated significantly with endoscopic disease activity, clinical activity index, CRP, and blood leucocytes. Furthermore, lactoferrin and calprotectin were suitable markers that can differentiate endoscopically and histopathologically inactive from active disease. Also TGF-B1 was used as a useful marker to distinguish mild from moderate and high active disease. Thus, these three biomarkers may be used for monitoring ulcerative colitis activity.

show abstract

“…Fecal calprotectin is a quantitative biomarker used to detect inflammation in intestinal mucosa . There are many causes that increase the level of faecal calprotectin .…”

Section: Discussionmentioning

confidence: 99%

Fecal calprotectin in children with familial Mediterranean fever in the attack‐free period

Demirbaş

Çaltepe

Comba

et al. 2019

Pediatrics International

View full text Add to dashboard Cite

Background Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized by recurrent episodes of fever and serosal inflammation. The aim of this study was to evaluate fecal calprotectin (FC) in children with FMF during the non‐attack period. Methods A retrospective evaluation was made of the data of a total 66 patients diagnosed with FMF in an attack‐free period and without amyloidosis or inflammatory bowel disease (IBD). FC level in the FMF patients was compared with that in the patients with IBD and healthy control subjects. Results The FMF patients consisted of 37 boys (56.1%) with a mean age of 10.1 ± 3.9 years. Mean FC was 192.5 μg/g (range, 19.5–800 μg/g) in the FMF group, 597.9 μg/g (range, 180–800 μg/g) in the IBD group, and 43.8 μg/g (range, 19.5–144 μg/g) in the control group. The FC level in the children with FMF was higher than in the control group (P < 0.001), and the FC level of the IBD patients was higher than both the FMF and the control groups (P = 0.020, P < 0.001, respectively). Conclusions FC was higher in FMF patients compared with healthy children even in the absence of IBD/amyloidosis. Even though colonoscopy is the gold standard in identifying intestinal inflammation in FMF patients, FC, a non‐invasive and inexpensive method, can be used for screening. The presence of subclinical intestinal inflammation was also quantitatively identified in children with FMF.

show abstract

FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms

Cited by 22 publications

References 35 publications

Importance of Measuring Levels of Infliximab in Patients Treating Inflammatory Bowel Disease in a Brazilian Cohort

Importance of Measuring Levels of Infliximab in Patients Treating Inflammatory Bowel Disease in a Brazilian Cohort

Fecal Lactoferrin, Fecal Calprotectin, Transforming growth factor-b1, and CRP in Evaluation of Disease Activity in Egyptian patients With Ulcerative colitis

Fecal calprotectin in children with familial Mediterranean fever in the attack‐free period

Contact Info

Product

Resources

About